C3 and paroxysmal nocturnal hemoglobinuria: Accordingly, recent clinical trials of the new C3-inhibitor, pegcetacoplan, have shown improved hematological outcomes in patients with PNH through targeting both hemolytic pathways [24]; however, there were no C3i patient data available at the time this analysis was conducted which should be addressed in a future study.